These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37567840)

  • 1. Atezolizumab-induced encephalitis with subdural hemorrhage and subarachnoid hemorrhage in a patient with hepatocellular carcinoma.
    Chao KH; Tseng TC
    J Formos Med Assoc; 2023 Nov; 122(11):1208-1212. PubMed ID: 37567840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atezolizumab- and bevacizumab -induced encephalitis in a patient with advanced hepatocellular carcinoma: a case report and literature review.
    Sagong M; Kim KT; Jang BK
    J Cancer Res Clin Oncol; 2024 Aug; 150(8):397. PubMed ID: 39180675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review.
    Özdirik B; Jost-Brinkmann F; Savic LJ; Mohr R; Tacke F; Ploner CJ; Roderburg C; Müller T
    Medicine (Baltimore); 2021 Jun; 100(24):e26377. PubMed ID: 34128898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab-induced Encephalitis in a Patient with Hepatocellular Carcinoma: A Case Report and Literature Review.
    Satake T; Maruki Y; Kubo Y; Takahashi M; Ohba A; Nagashio Y; Kondo S; Hijioka S; Morizane C; Ueno H; Okusaka T
    Intern Med; 2022 Sep; 61(17):2619-2623. PubMed ID: 35185051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab-associated encephalitis in metastatic lung adenocarcinoma: a case report.
    Yamaguchi Y; Nagasawa H; Katagiri Y; Wada M
    J Med Case Rep; 2020 Jul; 14(1):88. PubMed ID: 32620173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events.
    Hayashi H; Sawada K; Hasebe T; Nakajima S; Sawada J; Takiyama Y; Takiyama Y; Okumura T; Fujiya M
    Intern Med; 2022 Dec; 61(23):3497-3502. PubMed ID: 35491133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evans' syndrome induced by atezolizumab plus bevacizumab combination therapy in advanced hepatocellular carcinoma.
    Fukushima M; Tajima K; Sasaki R; Nakao Y; Takahashi K; Ozawa E; Miuma S; Kato T; Miyaaki H; Nakao K
    Clin J Gastroenterol; 2023 Jun; 16(3):402-406. PubMed ID: 36746879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
    Watanabe Y; Ogawa M; Tamura Y; Suda S; Kaneko M; Kumagawa M; Hirayama M; Matsumoto N; Yamamoto T; Moriyama M
    J Investig Med High Impact Case Rep; 2021; 9():23247096211058489. PubMed ID: 34845921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two cases of rapid progression of esophageal varices after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
    Furusawa A; Naganuma A; Suzuki Y; Hoshino T; Yasuoka H; Tamura Y; Naruse H; Hatanaka T; Kakizaki S
    Clin J Gastroenterol; 2022 Apr; 15(2):451-459. PubMed ID: 35179703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma.
    Iwasaki S; Hidaka H; Uojima H; Hashimura M; Nabeta T; Sanoyama I; Wada N; Kubota K; Nakazawa T; Shibuya A; Koizumi W
    Clin J Gastroenterol; 2021 Aug; 14(4):1233-1239. PubMed ID: 34024039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three cases of immune-related hypopituitarism after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
    Furuichi N; Naganuma A; Kaburagi T; Suzuki Y; Hoshino T; Shibusawa N; Horiguchi S; Hatanaka T; Kakizaki S; Uraoka T
    Clin J Gastroenterol; 2023 Jun; 16(3):422-431. PubMed ID: 36821067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Case of Patient with Atezolizumab-induced Encephalitis in Hepatocellular Carcinoma.
    Otomo K; Fujita M; Sekine R; Sato H; Abe N; Sugaya T; Watanabe C; Takahata Y; Hayashi M; Abe K; Takahashi A; Ohira H
    Intern Med; 2024 Sep; ():. PubMed ID: 39261064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
    Yano S; Kawaoka T; Johira Y; Miura R; Kosaka M; Shirane Y; Murakami S; Amioka K; Naruto K; Ando Y; Kosaka Y; Yamaoka K; Kodama K; Uchikawa S; Fujino H; Ohno A; Nakahara T; Murakami E; Okamoto W; Yamauchi M; Imamura M; Mori K; Arihiro K; Kuroda S; Kobayashi T; Ohdan H; Aikata H
    Medicine (Baltimore); 2021 Oct; 100(42):e27576. PubMed ID: 34678902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two cases of hepatocellular carcinoma successfully treated by carbon ion radiotherapy after atezolizumab plus bevacizumab treatment.
    Takakusagi S; Tanaka H; Naganuma A; Kakizaki S; Shibuya K; Ohno T; Takagi H; Uraoka T
    Clin J Gastroenterol; 2023 Jun; 16(3):407-415. PubMed ID: 36750524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of HCC successfully treated with infliximab-steroid sequential therapy for small bowel perforation due to atezolizumab/bevacizumab combination therapy.
    Hagiwara S; Komeda Y; Nishida N; Yoshida A; Kudo M
    Cancer Rep (Hoboken); 2022 Nov; 5(11):e1721. PubMed ID: 36224043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperprogression in a Patient With Hepatocellular Cancer Treated With Atezolizumab and Bevacizumab: A Case Report and Review of Literature.
    Singh B; Kaur P; Maroules M
    J Investig Med High Impact Case Rep; 2021; 9():2324709621992207. PubMed ID: 33787380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.